SOURCE: NuPathe Inc.

NuPathe Inc.

November 08, 2011 17:37 ET

NuPathe to Report Third Quarter 2011 Results and Hold Conference Call on Monday, November 14, 2011

CONSHOHOCKEN, PA--(Marketwire - Nov 8, 2011) - NuPathe Inc. (NASDAQ: PATH), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, will report third quarter 2011 results on Monday, November 14, 2011, after the close of the U.S. financial markets. NuPathe will also host a conference call at 4:30 p.m. EST on the same day to discuss its third quarter 2011 financial results and recent operational highlights. NuPathe will also discuss its November 9, 2011, meeting with the U.S. Food and Drug Administration (FDA) regarding the complete response letter for its migraine patch. A question-and-answer session will follow NuPathe's remarks.

To participate on the live call, please dial 877-675-4749 (domestic) or +1-719-325-4765 (international), and provide the participant passcode 2444740 five to ten minutes before the start of the call. A replay of the call will be available for 90 days within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 2444740.

A live audio webcast of the call will be also available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on NuPathe's website for 90 days following the call.

About NuPathe
NuPathe Inc. (www.nupathe.com) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.

Contact Information

  • Investor Relations Contact:
    John Woolford
    Westwicke Partners, LLC
    (443) 213-0506
    john.woolford@westwicke.com

    Keith A. Goldan
    Vice President & Chief Financial Officer
    NuPathe Inc.
    (484) 567-0130

    Media Contact:
    Tiberend Strategic Advisors, Inc.
    Jason Rando
    212-827-0020
    jrando@tiberend.com